TrialSignal transduction and targeted therapy2025

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Chuanhua Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.